Cite
HARVARD Citation
Salloway, S. et al. (n.d.). P4–417: Incidence and clinical progression of placebo‐treated amyloid‐negative subjects with mild‐to‐moderate Alzheimer's disease (AD): Results from the phase III PET substudies of bapineuzumab and solanezumab. Alzheimer's & dementia. pp. P888-P889. [Online].